Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovyjollibet, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that comfortably beat Wall Street expectations. But the drugmaker said it expected sales growth to slow in 2025, as competition increases.

Novo Nordisk retains its title as Europe’s most valuable company, but its share price has dropped about 40 percent since it peaked last June as analysts have worried about uncertainty in demand for obesity drugs and the performance of new drugs in trials.

Over the years, Ms. Judd told her son extremely little about her missing husband, who remained unaccounted for until May of this year. The Defense Department said earlier this month that her husband, Staff Sgt. John A. Tarbert of the Air Force was killed at 24 after his plane was attacked while flying over Germany 80 years ago this Friday.

jack and the beanstalk slot

The plaintiffs — who include Wendy Davis, a former Democratic state senator, along with a Biden campaign staff member and the bus driver — also testified, saying that the rolling road protest had been frightening and intimidating.

“Last year was a tale of two halves,windream” said Emily Field, an analyst at Barclays. The first half of 2024 offered “lots of overall excitement.”

But then data suggested that prescriptions for obesity drugs were growing slowly in the United States, and a few trial results for drugs in the company’s pipeline came in lower than expected, Ms. Field added. President Trump’s election also weighed on pharmaceutical companies in general amid potential changes to health care policy.

There has been “a lot of uncertainty,” she said, as investors have grown more concerned about whether sales of obesity drugs could really meet the industry’s lofty expectations of a market larger than $100 billion in the coming decades. Novo Nordisk’s main competitor is the American drugmaker Eli Lilly, which also sells obesity drugs.

On Wednesday, Novo Nordisk said its revenue jumped 25 percent last year to 290 billion Danish kroner, or $40.6 billion, driven by growing sales in the United States, and reported profit of more than 100 billion Danish kroner.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.

Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.jollibet